Key facts
- Terrana Biosciences’s last known valuation is $189.5M (Jul 2025).
- It has raised $83.0M; the latest was Early Stage VC ($50.0M) in Jul 2025.
- Notable investors include Flagship Pioneering.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Terrana Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Terrana Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Terrana Biosciences
Developer of an RNA-based agricultural platform designed to enhance plant health by addressing challenges from seed to post-harvest. The company offers a generative RNA technology that interprets biological signals and delivers adaptable plant care, enabling farmers and growers to combat pests and diseases, strengthen resilience to climate change, and improve soil vitality.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 49
- Website
- terranabio.com/
- Ownership
- Privately Held (backing)
Terrana Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Terrana Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Terrana Biosciences in its N-PORT filings yet. We sweep new filings monthly.